NON-SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON-SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Liver radiation boosts immunotherapy in advanced lung cancer trial
Disease control Recruiting nowThis study tests whether adding a precise, high-dose radiation treatment to the liver (L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either standard dru…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope for tough lung cancer: experimental drug faces off against standard chemo
Disease control Recruiting nowThis study tests a new drug, PF-08046054, against the standard chemo docetaxel in people with advanced non-small cell lung cancer that has PD-L1 protein and has stopped responding to prior treatments. About 680 adults will be randomly assigned to one of the two drugs, given as IV…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 04:08 UTC
-
New hope for lung cancer patients whose treatment stopped working
Disease control Recruiting nowThis study tests a combination of two targeted drugs, lazertinib and tepotinib, in people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) that has stopped responding to lazertinib alone due to a change in the MET gene. About 47 participants w…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
Immune cells from your own tumor could fight lung cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Blood test may spare lung cancer patients from useless treatments
Disease control Recruiting nowThis study tests whether regular blood tests (liquid biopsies) can help doctors monitor treatment in 350 people with advanced non-small cell lung cancer who are receiving immunotherapy. The goal is to see if this approach reduces the number of ineffective treatments and unnecessa…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Zealand University Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Brain mets showdown: pill plus radiation may beat pill alone in lung cancer
Disease control Recruiting nowThis study looks at people with a type of lung cancer (NSCLC) that has spread to the brain. They are already taking a targeted pill (osimertinib). The researchers want to see if adding a precise, one-time radiation treatment (SRS) after 3 months of the pill is better than just co…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Blood test may guide smarter lung cancer therapy
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors decide if adding chemotherapy to the immunotherapy drug cemiplimab improves survival in people with advanced non-small cell lung cancer. About 63 adults with stage IV or stage IIIB/C lung cancer that has not been trea…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New antibody aims to stall advanced cancers
Disease control Recruiting nowThis study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread and have a specific marker (FGFR1). The drug is an antibody given by IV every two weeks. The goal is to find a safe dose and see if it can slow tumor growth. About 58 adults with …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Kidney Cancer Research Bureau • Aim: Disease control
Last updated May 19, 2026 11:52 UTC
-
Protein test could tailor lung cancer therapy for better survival
Disease control Recruiting nowThis study tests whether using a protein-based test to choose treatment can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard therapy …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New study tracks Real-Life results of amivantamab combo for tough lung cancer
Knowledge-focused Recruiting nowThis study is watching how well a treatment combining amivantamab and chemotherapy works in everyday medical practice for adults with metastatic non-small cell lung cancer that has certain EGFR gene changes. About 100 people who are already getting this treatment through an early…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Sponsor: GFPC Investigation • Aim: Knowledge-focused
Last updated May 26, 2026 03:55 UTC
-
Italian study tracks Real-Life results of new lung cancer combo therapy
Knowledge-focused Recruiting nowThis study is collecting information from 300 people in Italy with advanced non-small cell lung cancer who are receiving a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment. The goal is to see how well this treatment work…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC